{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:09:39Z","timestamp":1785841779453,"version":"3.56.0"},"reference-count":115,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HAB"],"published-print":{"date-parts":[[2024,7,24]]},"abstract":"<jats:p>Following infection and vaccination against SARS-CoV-2, humoral components of the adaptive immune system play a key role in protecting the host. Specifically, B cells generate high-affinity antibodies against various antigens of the virus. In this review, we discuss the mechanisms of immunity initiation through both natural infection and vaccination, shedding light on the activation of B cell subsets in response to SARS-CoV-2 infection and vaccination. The innate immune system serves as the initial line of primary and nonspecific defence against viruses. However, within several days following infection or a vaccine dose, a virus-specific immune response is initiated, primarily by B cells that produce antibodies. These antibodies contribute to the resolution of the disease. Subsequently, these B cells transition into memory B cells, which play a crucial role in providing long-term immunity against the virus. CD4+ T helper cells initiate a cascade, leading to B cell somatic hypermutation, germinal center memory B cells, and the production of neutralizing antibodies. B-cell dysfunction can worsen disease severity and reduce vaccine efficacy. Notably, individuals with B cell immunodeficiency show lower IL-6 production. Furthermore, this review delves into several aspects of immune responses, such as hybrid immunity, which has shown promise in boosting broad-spectrum protection. Cross-reactive immunity is under scrutiny as well, as pre-existing antibodies can offer protection against the disease. We also decipher breakthrough infection mechanisms, especially with the novel variants of the virus. Finally, we discuss some potential therapeutic solutions regarding B cells including convalescent plasma therapy, B-1 cells, B regulatory cell (Breg) modulation, and the use of neutralizing monoclonal antibodies in combating the infection. Ongoing research is crucial to grasp population immunity trends and assess the potential need for booster doses in maintaining effective immune responses against potential viral threats.<\/jats:p>","DOI":"10.3233\/hab-230017","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:24:07Z","timestamp":1715952247000},"page":"85-106","source":"Crossref","is-referenced-by-count":4,"title":["Unravelling humoral immunity in SARS-CoV-2: Insights from infection and vaccination"],"prefix":"10.1177","volume":"32","author":[{"given":"Nouhaila","family":"Najimi","sequence":"first","affiliation":[{"name":"Laboratory of Human Pathologies Biology and Center of Genomic of Human Pathologies Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco"},{"name":"Mohammed VI Center for Research and Innovation, Rabat, Morocco"},{"name":"Mohammed VI University of Sciences and Health, Casablanca, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaimae","family":"Kadi","sequence":"additional","affiliation":[{"name":"Mohammed VI Center for Research and Innovation, Rabat, Morocco"},{"name":"Mohammed VI University of Sciences and Health, Casablanca, Morocco"},{"name":"Laboratory of Biology and Health, Faculty of Sciences of T\u00e9touan, Abdelmalek Essa\u00e2di University, T\u00e9touan, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noureddine","family":"Elmtili","sequence":"additional","affiliation":[{"name":"Laboratory of Biology and Health, Faculty of Sciences of T\u00e9touan, Abdelmalek Essa\u00e2di University, T\u00e9touan, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Seghrouchni","sequence":"additional","affiliation":[{"name":"Mohammed VI Center for Research and Innovation, Rabat, Morocco"},{"name":"Mohammed VI University of Sciences and Health, Casablanca, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bakri","sequence":"additional","affiliation":[{"name":"Laboratory of Human Pathologies Biology and Center of Genomic of Human Pathologies Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/HAB-230017_ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03323-w"},{"key":"10.3233\/HAB-230017_ref3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response","volume":"14","author":"Astuti","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"10.3233\/HAB-230017_ref4","doi-asserted-by":"publisher","first-page":"646333","DOI":"10.3389\/fimmu.2021.646333","article-title":"Cellular Immune Response to COVID-19 and Potential Immune Modulators","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","article-title":"Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.3233\/HAB-230017_ref6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.medj.2021.03.013","article-title":"Alterations in T and B cell function persist in convalescent COVID-19 patients","volume":"2","author":"Shuwa","year":"2021","journal-title":"Med."},{"key":"10.3233\/HAB-230017_ref7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.3233\/HAB-230017_ref8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","article-title":"Maturation and persistence of the anti-SARS-CoV-2 memory B cell response","volume":"184","author":"Sokal","year":"2021","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018571108"},{"key":"10.3233\/HAB-230017_ref10","unstructured":"Long term humoral immunity.pdf, (n.d.)."},{"key":"10.3233\/HAB-230017_ref11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ygeno.2020.09.059","article-title":"Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection","volume":"113","author":"Rahimi","year":"2021","journal-title":"Genomics."},{"key":"10.3233\/HAB-230017_ref12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/vaccines10020174","article-title":"Determinants of the Development of SARS-CoV-2 Anti-Spike Immune-Response after Vaccination among Healthcare Workers in Egypt","volume":"10","author":"El-Ghitany","year":"2022","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41392-021-00523-5","article-title":"SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.3233\/HAB-230017_ref14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.3233\/HAB-230017_ref15","doi-asserted-by":"publisher","first-page":"e0288557","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study","volume":"18","author":"Amellal","year":"2023","journal-title":"PLOS ONE."},{"key":"10.3233\/HAB-230017_ref16","doi-asserted-by":"publisher","first-page":"e0281689","DOI":"10.1371\/journal.pone.0281689","article-title":"Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals","volume":"18","author":"Al-Tamimi","year":"2023","journal-title":"PLOS ONE."},{"key":"10.3233\/HAB-230017_ref17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.coi.2006.07.010","article-title":"B-1 B cells: development, selection, natural autoantibody and leukemia","volume":"18","author":"Hardy","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.3233\/HAB-230017_ref18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.3233\/HAB-230017_ref19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S1074-7613(01)00129-7","article-title":"Marginal Zone and B1 B Cells Unite in the Early Response against T-Independent Blood-Borne Particulate Antigens","volume":"14","author":"Martin","year":"2001","journal-title":"Immunity."},{"key":"10.3233\/HAB-230017_ref20","doi-asserted-by":"publisher","first-page":"611004","DOI":"10.3389\/fimmu.2020.611004","article-title":"B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients","volume":"11","author":"Sosa-Hern\u00e1ndez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.chom.2021.06.009","article-title":"Antibody and B cell responses to SARS-CoV-2 infection and vaccination","volume":"29","author":"R\u00f6ltgen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.3233\/HAB-230017_ref22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","article-title":"The germinal centre B cell response to SARS-CoV-2","volume":"22","author":"Laidlaw","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.3233\/HAB-230017_ref23","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_675_21"},{"key":"10.3233\/HAB-230017_ref24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal Center B Cell Dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity."},{"key":"10.3233\/HAB-230017_ref25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/978-1-4939-8648-4_24","article-title":"The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies","author":"Bowers","year":"2018","journal-title":"Antib. Eng."},{"key":"10.3233\/HAB-230017_ref26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref27","doi-asserted-by":"publisher","first-page":"709533","DOI":"10.3389\/fbinf.2021.709533","article-title":"Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive Immunity","volume":"1","author":"Moody","year":"2021","journal-title":"Front. Bioinforma."},{"key":"10.3233\/HAB-230017_ref28","doi-asserted-by":"publisher","first-page":"610688","DOI":"10.3389\/fimmu.2020.610688","article-title":"Humoral Responses and Serological Assays in SARS-CoV-2 Infections","volume":"11","author":"Galipeau","year":"2020","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/cells11010067","article-title":"Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology","volume":"11","author":"Khanolkar","year":"2021","journal-title":"Cells."},{"key":"10.3233\/HAB-230017_ref30","doi-asserted-by":"publisher","first-page":"e0244855","DOI":"10.1371\/journal.pone.0244855","article-title":"Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration","volume":"16","author":"Newell","year":"2021","journal-title":"PLOS ONE."},{"key":"10.3233\/HAB-230017_ref31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/postgradmedj-2021-140540","article-title":"Memory B cells and serum immunoglobulins are associated with disease severity and mortality in patients with COVID-19","volume":"98","author":"\u00c7\u00f6lkesen","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"10.3233\/HAB-230017_ref32","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/vaccines9121376","article-title":"Overview of Neutralizing Antibodies and Their Potential in COVID-19","volume":"9","author":"Morales-N\u00fa\u00f1ez","year":"2021","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref33","doi-asserted-by":"publisher","first-page":"825813","DOI":"10.3389\/fimmu.2021.825813","article-title":"Generation of High Quality Memory B Cells","volume":"12","author":"Inoue","year":"2022","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","article-title":"B cell memory: understanding COVID-19","volume":"54","author":"Quast","year":"2021","journal-title":"Immunity."},{"key":"10.3233\/HAB-230017_ref35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00705-023-05773-y","article-title":"B lymphocytes in COVID-19: a tale of harmony and discordance","volume":"168","author":"Mansourabadi","year":"2023","journal-title":"Arch. Virol."},{"key":"10.3233\/HAB-230017_ref36","doi-asserted-by":"publisher","first-page":"e0261656","DOI":"10.1371\/journal.pone.0261656","article-title":"SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease","volume":"16","author":"Reyes","year":"2021","journal-title":"PLOS ONE."},{"key":"10.3233\/HAB-230017_ref37","doi-asserted-by":"publisher","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","article-title":"Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence","volume":"5","author":"Hartley","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.3233\/HAB-230017_ref38","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science."},{"key":"10.3233\/HAB-230017_ref39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","article-title":"Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19","volume":"184","author":"Rodda","year":"2021","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref40","unstructured":"S. Winklmeier, K. Eisenhut, D. Taskin, H. R\u00fcbsamen, P. Eichhorn, O.T. Keppler, M. Klein, S. Mader and E. Meinl, Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG, (n.d.)."},{"key":"10.3233\/HAB-230017_ref41","doi-asserted-by":"publisher","first-page":"988536","DOI":"10.3389\/fimmu.2022.988536","article-title":"The role of B cells in COVID-19 infection and vaccination","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/cid\/ciab646","article-title":"Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis","volume":"74","author":"Chen","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.3233\/HAB-230017_ref43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/vaccines9080910","article-title":"Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination","volume":"9","author":"Altawalah","year":"2021","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref44","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref45","doi-asserted-by":"publisher","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"R\u00f6ltgen","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.3233\/HAB-230017_ref46","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.immuni.2021.05.001","article-title":"Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets","volume":"54","author":"Dugan","year":"2021","journal-title":"Immunity."},{"key":"10.3233\/HAB-230017_ref47","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2666-5247(21)00219-6","article-title":"The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study","volume":"2","author":"Townsend","year":"2021","journal-title":"Lancet Microbe."},{"key":"10.3233\/HAB-230017_ref48","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.3233\/HAB-230017_ref49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/vaccines8030404","article-title":"COVID-19: Mechanisms of Vaccination and Immunity","volume":"8","author":"Speiser","year":"2020","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/fvl-2018-0008","article-title":"Post-translational modifications of coronavirus proteins: roles and function","volume":"13","author":"Fung","year":"2018","journal-title":"Future Virol."},{"key":"10.3233\/HAB-230017_ref51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and Prospects on Vaccine Development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref52","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1002\/jcp.30483","article-title":"Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity","volume":"236","author":"Ojha","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.3233\/HAB-230017_ref53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA."},{"key":"10.3233\/HAB-230017_ref54","doi-asserted-by":"publisher","first-page":"889","DOI":"10.7150\/ijbs.68973","article-title":"A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.3233\/HAB-230017_ref55","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.26.2100557"},{"key":"10.3233\/HAB-230017_ref56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref57","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.473537"},{"key":"10.3233\/HAB-230017_ref58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature."},{"key":"10.3233\/HAB-230017_ref59","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.31.466651"},{"key":"10.3233\/HAB-230017_ref60","doi-asserted-by":"publisher","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.3233\/HAB-230017_ref61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection","volume":"13","author":"Gobbi","year":"2021","journal-title":"Viruses."},{"key":"10.3233\/HAB-230017_ref62","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/vaccines11020355","article-title":"One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test","volume":"11","author":"Tuyji Tok","year":"2023","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref63","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.3233\/HAB-230017_ref64","doi-asserted-by":"publisher","first-page":"851861","DOI":"10.3389\/fmed.2022.851861","article-title":"Tracking SARS-CoV-2 Variants Using a Rapid Typification Strategy: A Key Tool for Early Detection and Spread Investigation of Omicron in Argentina","volume":"9","author":"Castro","year":"2022","journal-title":"Front. Med."},{"key":"10.3233\/HAB-230017_ref65","doi-asserted-by":"publisher","first-page":"105465","DOI":"10.1016\/j.isci.2022.105465","article-title":"Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster","volume":"25","author":"Peng","year":"2022","journal-title":"iScience."},{"key":"10.3233\/HAB-230017_ref66","doi-asserted-by":"publisher","first-page":"945930","DOI":"10.3389\/fimmu.2022.945930","article-title":"A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines","volume":"13","author":"He","year":"2022","journal-title":"Front. Immunol."},{"key":"10.3233\/HAB-230017_ref67","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.29.21266947"},{"key":"10.3233\/HAB-230017_ref68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/vaccines10030465","article-title":"Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers","volume":"10","author":"Assaid","year":"2022","journal-title":"Vaccines."},{"key":"10.3233\/HAB-230017_ref69","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3390\/v14091916","article-title":"Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation","volume":"14","author":"Azamor","year":"2022","journal-title":"Viruses."},{"key":"10.3233\/HAB-230017_ref70","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell."},{"key":"10.3233\/HAB-230017_ref71","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45531"},{"key":"10.3233\/HAB-230017_ref72","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/jmv.27644","article-title":"Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies","volume":"94","author":"Petrelli","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.3233\/HAB-230017_ref73","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.3233\/HAB-230017_ref74","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.09.459504"},{"key":"10.3233\/HAB-230017_ref75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature."},{"key":"10.3233\/HAB-230017_ref76","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature."},{"key":"10.3233\/HAB-230017_ref77","doi-asserted-by":"publisher","first-page":"112911","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ. Res."},{"key":"10.3233\/HAB-230017_ref78","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden","volume":"22","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.3233\/HAB-230017_ref79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tim.2016.09.001","article-title":"Molecular Evolution of Human Coronavirus Genomes","volume":"25","author":"Forni","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.3233\/HAB-230017_ref80","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s10875-021-00997-6","article-title":"Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses","volume":"41","author":"Hicks","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.3233\/HAB-230017_ref81","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans","volume":"370","author":"Ng","year":"2020","journal-title":"Science."},{"key":"10.3233\/HAB-230017_ref82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.chom.2021.12.005","article-title":"Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response","volume":"30","author":"Lin","year":"2022","journal-title":"Cell Host Microbe."},{"key":"10.3233\/HAB-230017_ref83","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/microorganisms8121993","article-title":"HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic","volume":"8","author":"Simula","year":"2020","journal-title":"Microorganisms."},{"key":"10.3233\/HAB-230017_ref84","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell\u2013derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.3233\/HAB-230017_ref85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.20411\/pai.v6i1.435","article-title":"COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review","volume":"6","author":"Jones","year":"2021","journal-title":"Pathog. Immun."},{"key":"10.3233\/HAB-230017_ref86","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3138\/jammi-2021-0036","article-title":"Reinfection with SARS-CoV-2 in a patient undergoing chemotherapy for lymphoma: Case report","volume":"7","author":"C\u00f4t\u00e9","year":"2022","journal-title":"Off. J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"10.3233\/HAB-230017_ref87","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21258990"},{"key":"10.3233\/HAB-230017_ref88","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1038\/s41467-022-32254-8","article-title":"Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections","volume":"13","author":"St\u00e6rke","year":"2022","journal-title":"Nat. Commun."},{"key":"10.3233\/HAB-230017_ref89","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/14760584.2021.1976153","article-title":"Impact of the Delta variant on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines."},{"key":"10.3233\/HAB-230017_ref90","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine Breakthrough Infections with SARS-CoV-2 Variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.3233\/HAB-230017_ref91","doi-asserted-by":"publisher","first-page":"e00072","DOI":"10.1128\/CMR.00072-20","article-title":"Convalescent Plasma Therapy for COVID-19: State of the Art","volume":"33","author":"Focosi","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.3233\/HAB-230017_ref92","unstructured":"H. Harvala, M.L. Robb, N. Watkins, S. Ijaz, S. Dicks, M. Patel, P. Supasa, W. Dejnirattisai, C. Liu, J. Mongkolsapaya, D. Bailey, R. Vipond, N. Grayson, N. Temperton, R.J. Ploeg, J. Bolton, A. Fyfe, R. Gopal, P. Simmonds, C. Thompson, T. Brooks, M. Zambon, G. Miflin and D.J. Roberts, Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels, (n.d.)."},{"key":"10.3233\/HAB-230017_ref93","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA."},{"key":"10.3233\/HAB-230017_ref94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"10.3233\/HAB-230017_ref95","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","volume":"92","author":"Ye","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.3233\/HAB-230017_ref96","doi-asserted-by":"publisher","first-page":"7758","DOI":"10.18632\/aging.202795","article-title":"Convalescent plasma to treat COVID-19: clinical experience and efficacy","volume":"13","author":"Pei","year":"2021","journal-title":"Aging."},{"key":"10.3233\/HAB-230017_ref97","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.18632\/aging.103102","article-title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging."},{"key":"10.3233\/HAB-230017_ref98","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.3233\/HAB-230017_ref99","doi-asserted-by":"publisher","first-page":"102820","DOI":"10.1016\/j.transci.2020.102820","article-title":"Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma","volume":"59","author":"Kong","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.3233\/HAB-230017_ref100","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s11739-020-02384-2","article-title":"Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol","volume":"15","author":"Perotti","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"10.3233\/HAB-230017_ref101","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12026-015-8708-3","article-title":"The role of B-1 cells in inflammation","volume":"63","author":"Aziz","year":"2015","journal-title":"Immunol. Res."},{"key":"10.3233\/HAB-230017_ref102","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-3-642-85226-8_17","article-title":"Structure and Function of Natural Antibodies","author":"Casali","year":"1996","journal-title":"Immunol. Silicones"},{"key":"10.3233\/HAB-230017_ref103","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1146\/annurev.iy.11.040193.002441","article-title":"Origin of Murine B Cell Lineages","volume":"11","author":"Kantor","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"10.3233\/HAB-230017_ref104","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1084\/jem.20101499","article-title":"Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70-","volume":"208","author":"Griffin","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.3233\/HAB-230017_ref105","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/SHK.0000000000001610","article-title":"Therapeutic Potential of B-1a Cells in COVID-19","volume":"54","author":"Aziz","year":"2020","journal-title":"Shock."},{"key":"10.3233\/HAB-230017_ref106","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.3233\/HAB-230017_ref107","doi-asserted-by":"publisher","first-page":"104753","DOI":"10.1016\/j.meegid.2021.104753","article-title":"New insights into regulatory B cells biology in viral, bacterial, and parasitic infections","volume":"89","author":"Sanaei","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"10.3233\/HAB-230017_ref108","doi-asserted-by":"publisher","first-page":"e0003543","DOI":"10.1371\/journal.pntd.0003543","article-title":"Leishmania infantum Amastigotes Trigger a Subpopulation of Human B Cells with an Immunoregulatory Phenotype","volume":"9","author":"Andreani","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.3233\/HAB-230017_ref109","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/1348-0421.12171","article-title":"Regulatory B cells correlate with HIV disease progression","volume":"58","author":"Jiao","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"10.3233\/HAB-230017_ref110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mmr.2017.6605","article-title":"Regulatory B cells in infectious disease","volume":"16","author":"Dai","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.3233\/HAB-230017_ref111","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B Cells: Origin, Phenotype, and Function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity."},{"key":"10.3233\/HAB-230017_ref112","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/mi.2010.8","article-title":"IL-10 production by CD4+ effector T cells: a mechanism for self-regulation","volume":"3","author":"Jankovic","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.3233\/HAB-230017_ref113","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/JLB.5COVCRA0721-387RR","article-title":"Circulating B10 regulatory cells are decreased in severe and critical COVID-19","volume":"112","author":"Cervantes-D\u00edaz","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.3233\/HAB-230017_ref114","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.3233\/HAB-230017_ref115","doi-asserted-by":"publisher","first-page":"e239694","DOI":"10.1001\/jamanetworkopen.2023.9694","article-title":"Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes","volume":"6","author":"Ambrose","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.3233\/HAB-230017_ref116","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Human Antibodies"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/HAB-230017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:46Z","timestamp":1777447366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/HAB-230017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":115,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/hab-230017","relation":{},"ISSN":["1875-869X","1093-2607"],"issn-type":[{"value":"1875-869X","type":"electronic"},{"value":"1093-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}